Human Genome Sciences Plans to Move LymphoStat-B To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm believes it can proceed with Phase III trials of the lupus agent based on subpopulation findings despite its failure to meet primary endpoints in Phase II.
You may also be interested in...
HGS Reports Long-Term Lymphostat-B Data In Lupus Patients
Data shows that belimumab resulted in a sustained improvement in disease activity through two and a half years.
HGS Reports Long-Term Lymphostat-B Data In Lupus Patients
Data shows that belimumab resulted in a sustained improvement in disease activity through two and a half years.
HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006
Full Phase II study results show promise in treatment of lupus even though Lymphostat-B did not meet primary endpoints, the firm says.